Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 7/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CCL5 | P13501 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641240 | 1.00 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1MAPTSMN1; SMN2TSHR | |
| SCHEMBL641389 | 0.92 | CCR5 (0.35) | CCR5CCL5CHRM1HSD11B1 | |
| SCHEMBL10008024 | 0.92 | CCR5 (0.35) | CCR5CCL5CHRM1HSD11B1 | |
| SCHEMBL640046 | 0.91 | CCR5 (0.36) | ALDH1A1SMN1; SMN2CCR5CCL5CHRM1 | |
| SCHEMBL640047 | 0.91 | CCR5 (0.36) | ALDH1A1SMN1; SMN2CCR5CCL5CHRM1 | |
| SCHEMBL639986 | 0.90 | MEN1 (0.34) | ALDH1A1SMN1; SMN2CCR5CCL5CHRM1 | |
| SCHEMBL639985 | 0.90 | MEN1 (0.34) | ALDH1A1SMN1; SMN2CCR5CCL5CHRM1 | |
| SCHEMBL641987 | 0.88 | PAX8 (0.35) | PKMPOLBCCR5CCL5CHRM1 | |
| SCHEMBL640693 | 0.88 | PAX8 (0.35) | PKMPOLBCCR5CCL5CHRM1 | |
| SCHEMBL641096 | 0.88 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2CCR5CCL5HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791148-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8119676-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | Abbott GmbH & Co. HG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | ALDH1A1 586/4885L3MBTL1 3180/4885MAPT 4368/4885 |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | ALDH1A1 586/4885L3MBTL1 3180/4885MAPT 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.